

## **ABSTRACT OF THE DISCLOSURE**

The present invention discloses the use of high affinity adenosine A<sub>3</sub> receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A<sub>3</sub> receptors and cancers expressing P-glycoprotein or MRP. In preferred  
5   embodiments, adenosine A<sub>3</sub> receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent.

339812.1